Tag: Gene Editing

Posted on

Field Focus: Precision Gene Editing with CRISPR

by
0 comments
Bacterial cells infected by viruses.
Bacterial cells can be infected by viruses (shown in red and purple) and have evolved ways to defend themselves. Credit: Stock image.

Like humans, bacteria can be infected by viruses and have evolved ways to defend themselves. Researchers are now adapting this bacterial “immune system” to precisely and efficiently edit genes in cells from humans and a wide range of other organisms. Scientists are excited about the tremendous potential of this powerful tool for advancing biomedical research and treating diseases.

The bacterial defense system is called CRISPR, for clustered regularly interspaced short palindromic repeats. A breakthrough in understanding CRISPR came from examining bacteria used by the dairy industry for the production of yogurt and cheese. In a study published in 2007, researchers showed that these bacteria insert viral DNA sequences into their own genomes and use that information to disarm the virus when it attacks again. Subsequent research has shown that the CRISPR system consists of small RNA molecules that target specific viral DNA sequences and proteins that cut the DNA, thus destroying the virus.

Researchers have already adapted CRISPR into a gene-editing tool that’s quicker, cheaper and more precise than existing methods. Researchers can use CRISPR to add, delete, rev up or tone down certain genes as well as create animal models for studying human diseases. The ability to precisely target genes in human cells is expected to speed progress in the development of gene-based therapies.

Although much is known about CRISPR, we still have a lot to learn. For example, how do bacterial cells obtain and insert the viral DNA into their genome? What triggers production of the CRISPR RNA molecules? How are invading viral DNAs targeted for destruction? This last question is answered in part by a pair of findings described in an earlier post, A Crisper View of the CRISPR Gene-Editing Mechanism. We also want to figure out how we can make the CRISPR gene-editing tool even more versatile and precise.

The CRISPR story offers a good example of how studying basic biological processes leads to new—and sometimes unexpected—insights and applications.

Emily Carlson also contributed to this blog post.

Related advances:
CRISPR/Cas9 Protein Complex Can Be Programmed to Recognize and Cleave RNA
CRISPR System Adapted to Reversibly Regulate Gene Expression

Posted on

A Crisper View of the CRISPR Gene-Editing Mechanism

by
0 comments
Structural model of the Cascade surveillance machine
Structural model of the Cascade surveillance machine. Credit: Ryan Jackson, Montana State University. Click for larger image

To dismantle the viruses that infect them, bacteria have evolved an immune system that identifies invading viral DNA and signals for its destruction. This gene-editing system is called CRISPR, and it’s being harnessed as a tool for modifying human genes associated with disease.

Taking another important step toward this potential application, researchers now know the structure of a key CRISPR component: a multi-subunit surveillance machine called Cascade that identifies the viral DNA. Shaped like a sea horse, Cascade is composed of 11 proteins and CRISPR-related RNA. A research team led by Blake Wiedenheft of Montana State University used X-ray crystallography and computational analysis to determine Cascade’s configuration. In a complementary study, Scott Bailey of Johns Hopkins University and his colleagues determined the structure of the complex bound to a viral DNA target.

Like blueprints, these structural models help scientists understand how Cascade assembles into an efficient surveillance machine and, more broadly, how the CRISPR system functions and how to adapt it as a tool for basic and clinical research.

Learn more:
Montana State University News Release Exit icon
Johns Hopkins University News Release Exit icon

Posted on

Making Strides in Genomic Engineering of Human Stem Cells

by
1 comment
Genetically engineered human stem cells. Credit: Jeff Miller, University of Wisconsin-Madison.
Genetically engineered human stem cells hold promise for basic biomedical research as well as for regenerative medicine. Credit: Jeff Miller, University of Wisconsin-Madison.

Human pluripotent stem cells (hPSCs) can multiply indefinitely and give rise to virtually all human cell types. Manipulating the genomes of these cells in order to remove, replace or correct specific genes holds promise for basic biomedical research as well as medical applications. But precisely engineering the genomes of hPSCs is a challenge. A research team led by Erik Sontheimer of Northwestern University and James Thomson of the Morgridge Institute for Research at the University of Wisconsin-Madison developed a technique that could be a great improvement over existing, labor-intensive methods. Their approach uses an RNA-guided enzyme from Neisseria meningitidis bacteria—part of a recently discovered bacterial immune system—to efficiently target and modify specific DNA sequences in the genome of hPSCs. The technique could eventually enable the repair or replacement of diseased or injured cells in people with some types of cancer, Parkinson’s disease and other illnesses.

This work also was funded by NIH’s National Center for Advancing Translational Sciences.

Learn more:

Thomson Bio Exit icon

Posted on

Silencing Extra Copy of Chromosome 21

by
0 comments

Each year about 1 in 700 babies is born with Down syndrome, a condition that occurs when cells contain three copies of chromosome 21. A new technique offers a proof of principle for silencing the extra copy. Using induced pluripotent stem cells derived from a person with Down syndrome, a research team led by Jeanne Lawrence of the University of Massachusetts Medical School inserted a gene called XIST into the extra chromosome 21. The gene, which normally turns off one whole X chromosome in females, rendered the chromosome copy and most of its genes inactive. The researchers plan to test the approach in a mouse model of Down syndrome and use it to further explore the biology of chromosome errors. The findings could eventually aid the development of therapies to mitigate resulting medical problems.

This work also was funded by NIH’s National Cancer Institute and Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Learn more:
University of Massachusetts Medical School News Release
Lawrence Lab Exit icon